OPEN END TURBO OPTIONSSCHEIN LONG - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 19:25:52 14/06/2024 BST | ||
| 15.67 EUR | +2.28% |
|
| Current month | +23.97% | ||
| 1 month | +49.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 15.67 | +2.28% |
| 13/06/24 | 15.32 | +2.20% |
| 12/06/24 | 14.99 | -4.22% |
| 11/06/24 | 15.65 | -0.63% |
| 10/06/24 | 15.75 | -0.51% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 07:25 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GK9DJX |
| ISIN | DE000GK9DJX7 |
| Date issued | 22/08/2022 |
| Strike | 315.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.19 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.84 € |
|---|---|
| Lowest since issue | 0.74 € |
| Spread | 0.2 € |
| Spread % | 1.27% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat